TGFB1 and pulmonary fibrosis: miR-101 plays an active role in inhibiting fibrotic diseases, such as renal (Ding et al., 2020), hepatic (Lei et al., 2019), or pulmonary fibrosis (Huang et al., 2017) and bladder outlet obstruction (Wang et al., 2019b), by directly targeting ALK5 in the canonical TGF-β signaling pathway.